news
Altasciences receives accreditation from College of American Pathologists
The College of American Pathologists has given accreditation to Altasciences’ clinical site in Los Angeles, California.
List view / Grid view
Research & Development
news
Simcere receives clearance to investigate a bi-functional fusion protein drug
The FDA has cleared the Simcere's investigational new drug application for SIM0237, an anti-PD-L1/IL-15 bi-functional fusion protein, for the treatment of adult patients with advanced solid tumours.
webinar
Techniques to reduce evaporation risk and cross-contamination by improving crystallisation screens
27 October 2022 | By SPT Labtech
In this webinar, you will get a practical walk-through of how to make consistent transfers from a deep well block to a crystal screening plate using an automated pipetting system and examine best practice setting up sitting-drop vapour diffusion crystallisation.
news
Automated liquid handlers market set to record $242.84m growth
A report has found that increased investment in drug discovery will help the demand for personalised medicine, encouraging the growth of the liquid handling market.
podcasts
Episode 13 – Multiplexing with Dr Luke Gammon, Queen Mary University & Dr David Pointu, Leica Microsystems
Join our experts as they discuss the advantages of multiplexed imaging for a wide range of research and how this technique will develop in the future.
article
Right model, right complexity: using in vitro human disease cell models in drug discovery
Ensuring that drug candidates can reach the clinic is no easy task, so having models that can closely represent human pathology is crucial. Here, Dr Beth Hoffman, CEO of Origami Therapeutics, describes the successes and challenges of using human disease cell models in drug discovery.
article
The hunt for new hepatitis treatments
In this exclusive interview for World Hepatitis Day with Drug Target Review, Professor Ziv Ben Ari from the Sheba Medical Center discusses recent progress towards hepatitis treatment.
news
Takeda enters agreement with F-star Therapeutics to license bispecific antibody
F-star Therapeutics has announced a licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.
news
Researchers create weakened version of SARS-CoV-2 that does not cause illness or death
Scientists have received approval to work with a weakened, non-harmful version of SARS-CoV-2 in biosafety level 2 laboratories, which makes it more efficient to study the virus, and to identify new treatments.
article
Chiral nanostructures could help accelerate drug discovery
A new photonic effect in semiconducting helical particles with nanoscale dimensions has been discovered by an international team of scientists from the University of Bath, UK and the University of Michigan, US. Here, Professors Nicholas Kotov and Ventsislav Valev discuss their study and the observed effect which has the potential…
article
Providing new hope for rare disease using non-viral gene therapy
Viral vectors to deliver gene therapies are utilised by clinically approved therapies. However, this method is not the only option for advanced therapeutics. In this piece, Brent Warner, President, Gene Therapy at Poseida Therapeutics, discusses the balance between efficacy and safety in gene therapy, highlighting positive pre-clinical data for non-viral…
article
Challenges and opportunities: lessons learned in developing potential gene therapy cures
While the full potential of gene therapies continues to be realised, their successes in rare diseases promote them as a promising treatment modality. Dr Gaurav Shah, Chief Executive Officer of Rocket Pharmaceuticals discusses the future of gene therapies as well as the company’s progress in in vivo and ex vivo programmes.
article
Drug Target Review Screening ebook
This ebook features insights into the discovery of a new non-linear chiroptical effect for characterising nanohelices in miniscule volumes, and a novel organoid drug-screening platform with numerous eco benefits.
news
Preclinical study highlights an effective combination immunotherapy for liver cancer
Study in mice significantly slowed liver tumour growth and activated anti-tumour immune response, highlighting an effective immunotherapy for liver cancer.
article
The legacy of COVID in vaccine research
Dr Owen Seddon, University Hospital of Wales, looks at how lessons learned during the pandemic can inform pre-clinical and early R&D phases of future vaccine work.
